Sotagliflozin significantly lowers Heart Attack and Stroke Risk, reports Lancet study Dr. Kamal Kant Kohli20 Feb 2025 3:30 AMSotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular risk factors, has been...
Study Links Elevated Beta-Hydroxybutyrate Levels to Increased DKA Risk in Type 1 Diabetes Patients on Sotagliflozin Medha Baranwal3 Oct 2024 3:30 AMUSA: A recent study published in Diabetes Technology & Therapeutics has revealed a concerning connection between elevated beta-hydroxybutyrate...
Sotagliflozin Cost-Effective for Heart Failure and Diabetes Patients, finds JACC Study Jacinthlyn Sylvia28 Jun 2024 3:30 AMA recent analysis of the SOLOIST-WHF trial published in the JACC: Heart Failure provided strong evidence on the cost-effectiveness of sotagliflozin...
Top Ten US-FDA Approved Pharmacological Agents in 2023: A Year in Review MDTV Bureau30 Dec 2023 10:21 AMWe come to the end of 2023. Here are top ten pharmacological agents that received US-FDA approval throughout this year, across key therapy areas:1)...
Sotagliflozin protects kidney and heart in patients with diabetes and CKD Dr Kartikeya Kohli6 Nov 2023 3:15 AMSodium-glucose cotransporter-2 (SGLT2) inhibitors are medications that lower blood sugar levels and also provide kidney- and heart-related...
Initiation of sotagliflozin before discharge in diabetes patients with worsening HF improves outcomes Niveditha Subramani16 Aug 2023 5:45 AMHeart failure (HF) is a most common disease characterized by variable durations of symptomatic stability often punctuated by episodes of worsening...
FDA Approves Sotagliflozin for Heart Failure Dr. Kamal Kant Kohli27 May 2023 3:45 AMThe US food and drug administration has approved Sotagliflozin once-daily oral tablet for reduction of risk for death, heart failure hospitalization...
Sotagliflozin effective and safe in reducing HbA1c among diabetes patients with CKD Medha Baranwal18 Feb 2023 4:45 AMUSA: Sotagliflozin 400 but not 200 mg significantly reduced HbA1c compared with placebo after 26 weeks in adults with type 2 diabetes (T2D) and stage...
Sotagliflozin exhibits metabolic benefits in diabetes with metabolic syndrome Dr.Niharika Harsha B9 Dec 2022 2:30 PMA new meta-analysis revealed that sotagliflozin has metabolic benefits like BP-lowering and weight loss and is a sensible remedial choice for treating...
Dual or single SGLT inhibition: which is more beneficial for type 2 diabetes? Study sheds light Medha Baranwal19 Oct 2022 4:00 AMIn type 2 diabetes patients, the study did not indicate different clinical impacts of dual and single SGLT inhibition.Germany: Inhibition of...
Sotagliflozin tied to reduced risk of MACE in patients with diabetes and CKD: SCORED Trial Medha Baranwal5 April 2022 5:45 AMUSA: Results from SCORED trial sheds light on the potent effect of the investigational SGLT1&2 inhibitor sotagliflozin on major cardiovascular...
Sotagliflozin use linked to reduced risk of heart attack, heart failure and stroke in diabetics: Study Medha Baranwal15 July 2021 3:30 AMSotagliflozin is not FDA approved and if it is brought to the market, it would signify a major advance in the care of patients with diabetes,...
